BTB Therapeutics, Inc. was originally founded in 2020 in Kyoto based on the transcriptomics drug discovery programs of Professor Masatoshi Hagiwara of Kyoto University. We are developing a non-opioid analgesic as a breakthrough modality to solve the opioid crisis. In addition, our pipeline includes RNA-modifying compounds to treat rare genetic diseases and to enhance the efficacy of cancer immunotherapy. We completed US corporate inversion in January 2025 and now BTB Therapeutics, Inc. is located in Escondido, CA with its operating subsidiary in Kyoto, Japan.

BTB Therapeutics, Inc.

Org chart

Teams

Offices